Literature DB >> 21856485

Medical therapy for chronic heart failure.

Henry Krum1, John R Teerlink.   

Abstract

Understanding of contemporary pharmacological therapy for chronic heart failure continues to evolve. In this Review, we discuss how findings from clinical trials have caused the roles of old therapies to be expanded and past treatment algorithms to be challenged. Several trials investigating preserved ejection fraction as a measure of heart failure had disappointing results, although important studies are in progress. Many novel therapeutic approaches for heart failure have emerged and are discussed in this review. The pharmacological treatments for heart failure continue to change, with many exciting possibilities for the future.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21856485     DOI： 10.1016/S0140-6736(11)61038-6

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  24 in total

Review 1.  Left ventricular restoration devices.

Authors:  Guilherme H Oliveira; Sadeer G Al-Kindi; Hiram G Bezerra; Marco A Costa
Journal:  J Cardiovasc Transl Res       Date:  2014-02-27       Impact factor: 4.132

2.  Prognostic relevance of heart rate at rest for survival and the quality of life in patients with dilated cardiomyopathy.

Authors:  Buntaro Fujita; Marcus Franz; Bjoern Goebel; Michael Fritzenwanger; Hans R Figulla; Friedhelm Kuethe; Markus Ferrari; Christian Jung
Journal:  Clin Res Cardiol       Date:  2012-03-28       Impact factor: 5.460

3.  A First-in-Human Study of AMG 986, a Novel Apelin Receptor Agonist, in Healthy Subjects and Heart Failure Patients.

Authors:  Peter Winkle; Steven Goldsmith; Michael J Koren; Serge Lepage; Jennifer Hellawell; Ashit Trivedi; Kate Tsirtsonis; Siddique A Abbasi; Allegra Kaufman; Richard Troughton; Adriaan Voors; Jean-Sebastien Hulot; Erwan Donal; Navid Kazemi; Joel Neutel
Journal:  Cardiovasc Drugs Ther       Date:  2022-04-23       Impact factor: 3.727

4.  Hydrogen Sulfide Reduces Recruitment of CD11b+Gr-1+ Cells in Mice With Myocardial Infarction.

Authors:  Ting Wu; Hua Li; Bing Wu; Lei Zhang; San-Wu Wu; Jia-Ning Wang; You-En Zhang
Journal:  Cell Transplant       Date:  2017-02-09       Impact factor: 4.064

5.  [Pilot study of levosimendan : Effect on liver blood flow and liver function in acute decompensated heart failure].

Authors:  K Lenz; A Gegenhuber; F Firlinger; G Lohr; P Piringer
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-04-19       Impact factor: 0.840

6.  An Injectable Microparticle Formulation Provides Long-Term Inhibition of Hypothalamic ERK1/2 Activity and Sympathetic Excitation in Rats with Heart Failure.

Authors:  Youssef W Naguib; Yang Yu; Shun-Guang Wei; Angie Morris; Brittany E Givens; Aml I Mekkawy; Robert M Weiss; Robert B Felder; Aliasger K Salem
Journal:  Mol Pharm       Date:  2020-08-04       Impact factor: 4.939

Review 7.  Reviewing the medical literature: five notable articles in general internal medicine from 2010 and 2011.

Authors:  Alexander A Leung; Carl van Walraven
Journal:  Open Med       Date:  2012-02-14

8.  Clinical effects of Xinmailong therapy in patients with chronic heart failure.

Authors:  Qilin Ma; Youxi Luo; Pi Guo; Gan Gao; Meixue Yang; Gaurav Sablok; Yanchun Zhang; Fengfeng Zhou
Journal:  Int J Med Sci       Date:  2013-03-23       Impact factor: 3.738

9.  Deleterious effect of the IL-23/IL-17A axis and γδT cells on left ventricular remodeling after myocardial infarction.

Authors:  Xiaoxiang Yan; Takashi Shichita; Yoshinori Katsumata; Tomohiro Matsuhashi; Hideyuki Ito; Kentaro Ito; Atsushi Anzai; Jin Endo; Yuichi Tamura; Kensuke Kimura; Jun Fujita; Ken Shinmura; Weifeng Shen; Akihiko Yoshimura; Keiichi Fukuda; Motoaki Sano
Journal:  J Am Heart Assoc       Date:  2012-10-25       Impact factor: 5.501

10.  Validation of prescribing appropriateness criteria for older Australians using the RAND/UCLA appropriateness method.

Authors:  Benjamin Joseph Basger; Timothy Frank Chen; Rebekah Jane Moles
Journal:  BMJ Open       Date:  2012-09-14       Impact factor: 2.692
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.